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Abstract 
Objective: The nonsteroidal anti-inflammatory drug (NSAID) diclofenac epolamine (DHEP) 
formulated as a topical patch has demonstrated efficacy and safety in the localized treatment 
of acute pain from minor strains, sprains, and contusions, and for epicondylitis and knee 
osteoarthritis. The glycosaminoglycan heparin enhances the activity of topical NSAIDs 
formulated as a medicated plaster, even in the absence of any significant release of heparin. 
Therefore, DHEP Plus, a new formulation of the DHEP medicated plaster containing a small 
amount of heparin sodium as excipient has been developed.  
Methods: We reviewed the pivotal and supportive studies of the clinical development 
program of the new patch and evaluated the role of heparin as an enhancer in the treatment 
of localized pain/inflammation of musculoskeletal structures, associated with post-traumatic 
and/or rheumatic conditions. 
Results: The data were consistent with the concept that heparin increased the clinical activity 
of the DHEP Plus medicated plaster versus the reference DHEP medicated plaster through 
improved bioavailability due to enhanced movement of diclofenac from the plaster. Both 
DHEP formulations have the same dissolution profile, indicating that heparin does not change 
the physical and chemical characteristics of the plaster. Permeation testing showed that 
heparin is not released from the DHEP Plus medicated plaster. Efficacy studies showed that 
the DHEP Plus medicated plaster was significantly more effective in reducing pain than the 
reference marketed DHEP medicated plaster.  
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 Conclusions: The benefit/risk assessment of DHEP Plus 180 mg medicated plaster is favorable, 
with a safety profile equal to placebo and improved efficacy over the reference marketed 
DHEP medicated plaster. 
 
Short title: Development of a diclofenac epolamine medicated plaster with heparin as excipient 
Keywords: nonsteroidal anti-inflammatory drugs; diclofenac epolamine patch; heparin; 
excipients; pain 
 
 
 
 
 
1. Introduction 
Topical formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) have been developed with 
the aim of reducing the systemic impact of NSAIDs. As a class, NSAIDs are associated with a number 
of adverse effects, including gastrointestinal complications, nephrotoxicity, and cardiovascular 
events1-7. Topical NSAID formulations are designed to deliver effective analgesic activity when locally 
applied while limiting systemic exposure. A recent analysis of the Cochrane Database of Systematic 
Reviews concluded that topical NSAIDs are safe and effective in helping to reduce pain associated 
with acute sprains and strains and that topical NSAIDs, specifically diclofenac and ketoprofen, may 
provide useful levels of pain relief in osteoarthritis8-10. In acute musculoskeletal pain conditions such 
as strains and sprains, the number needed to treat (NNT) to achieve ≥50% pain relief when used for 
approximately 7 days was between 1.8 and 4.7 depending on the active substance and 
formulation9,11. For chronic pain musculoskeletal conditions, predominantly hand and knee 
osteoarthritis, the NNT for topical diclofenac preparations was 5.0 when used for <6 weeks, 9.8 for 
>6–12 weeks, and 6.9 for ketoprofen gel used for >6–12 weeks9. Comparisons other than placebo 
were limited, but data from the 5 studies reviewed found that the proportion of participants 
achieving treatment success was 55% with topical NSAIDs and 54% with oral preparations8. Of 
interest, a recent systematic review and network meta-analysis of randomized controlled trials and 
observational studies of topical NSAIDs (including gels, solutions, creams, and medicated plasters) in 
osteoarthritis concluded that they were effective and safe for knee osteoarthritis and determined 
that diclofenac medicated plasters were more effective than other topical NSAID formulations12. 
There is substantive evidence, based on large, good quality trials, that topical NSAIDs reduce the 
incidence of systemic complications, including gastrointestinal ulceration and bleeding, compared 
with systemic NSAIDs8,9,13-15. The majority of the published evidence base for topical NSAIDs is 
related to formulations of diclofenac, a commonly-used NSAID which inhibits both isoforms of 
cyclooxygenase (COX), COX-1 and COX-216 and has demonstrated anti-inflammatory, analgesic and 
antipyretic activity resulting from the inhibition of prostaglandin synthesis8,9,17,18. 
A topical patch formulation of diclofenac epolamine (diclofenac hydroxyethylpyrrolidine, DHEP) 
1.3%19, developed by IBSA Institut Biochimique S.A. (Lugano, Switzerland) was approved for use in 
Europe in 1993 and in the United States (USA) in 2007 (Flector® Tissugel 1%; Flector® Patch 1.3%)20 
for symptomatic treatment of localized pain and inflammatory conditions affecting joints, muscle, 
tendon, and ligaments for adults and adolescents older than 16 years. This is specifically indicated 
for the topical treatment of acute pain from minor strains, sprains, and contusions, as well as for 
epicondylitis and knee OA in Europe.  
The safety and efficacy of the marketed DHEP medicated plaster have been demonstrated by 
data from clinical studies and postmarketing experience of the treatment of acute musculoskeletal 
pain associated with soft tissue injuries and inflammatory pathologies, including osteoarthritis and 
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 other rheumatological conditions5,8,9,21-26. Results from a skin permeability and pharmacokinetic 
study10 and a pharmacokinetic study in healthy volunteers27 show that the systemic exposure of 
diclofenac is very low compared with oral administration when applied as the DHEP medicated 
plaster. The systemic exposure to the DHEP medicated plaster at steady state, after 4 days of twice-
daily application, was over 99% less than after a single oral dose of diclofenac27. This in accordance 
with the findings from a relevant animal model, which showed that penetration of diclofenac into 
the underlying muscle when applied as a medicated plaster was sustained and appeared to follow 
zero-order kinetics, while systemic bioavailability and distribution into other tissues was very 
limited10. Similar concentrations of diclofenac in the immediate tissue underlying the patch area 
were obtained with both topical and 50 mg oral administration of diclofenac10.  
In comparison, other studies with gel formulations of diclofenac applied to give total daily doses 
between 5 and 40 mg diclofenac have been shown to yield formulation-dependent plasma 
diclofenac concentrations ranging from approximately 1.1 to 8.2 ng/mL, which were higher than 
both subcutaneous and muscle diclofenac microdialysate concentrations, and were at least 150 
times lower than those achieved after oral dosing28. 
Recently, topically-applied heparins, have been utilized for their anti-inflammatory properties 
and micro-vascular activity for prevention and the treatment of local symptoms (i.e., pain, edema) 
associated with peripheral vascular disorders29.  
The absorption through the skin of topical formulations may be enhanced by gentle rubbing 
during application of the cream or gel. Here, the absorption of heparin from the sticky poultice base 
of a medicated plaster is negligible. It has been postulated that heparin, as an excipient, may have 
other properties that enhance the activity of topical NSAIDs formulated as a medicated plaster, even 
in the absence of any significant release of heparin from the plaster. To exploit these effects, DHEP 
Plus medicated plaster (Flectormed®1, containing DHEP 180 mg, corresponding to 140 mg diclofenac 
sodium) was developed as a new formulation of the reference marketed DHEP medicated plaster.  
The DHEP Plus medicated plaster is identical to the marketed DHEP medicated plaster, 
except for the presence in the formulation of a relatively small amount of unfractionated heparin 
sodium of porcine origin.  
This critical review summarizes the clinical development process of the DHEP Plus medicated 
plaster and discusses the role of heparin sodium as an enhancer in the treatment of localized pain 
and inflammation of musculoskeletal structures, associated with post-traumatic and/or rheumatic 
conditions. Published studies identified in Embase and MEDLINE (via PubMed) have been reviewed 
together with unpublished data on file from the clinical development program of the DHEP Plus 180 
mg medicated plaster provided by IBSA Institut Biochimique S.A. 
2. Characteristics of the DHEP Plus 180 mg medicated plaster 
2.1 Clinical pharmacology of diclofenac epolamine 
Diclofenac is a commonly used NSAID with well-established analgesic and anti-inflammatory 
activities resulting from the inhibition of COX-1 and COX-2 isoenzymes and reduced prostaglandin 
synthesis16, but with a four-fold selectivity for COX-230. Inhibition of COX-2 reduces pain and 
inflammation. The analgesic efficacy of diclofenac epolamine when administered topically in plaster 
or gel form has been demonstrated in the symptomatic treatment of various painful local conditions 
of different origins, such as knee osteoarthritis31,32, localized inflammatory diseases33, inflammatory 
peri- and extra-articular rheumatic diseases34, minor sport injuries35,36, shoulder periarthritis and 
lateral epicondylitis37, peri- and extraarticular inflammatory diseases38, sprains, strains and 
contusions39. 
                                                 
1
 Other available tradenames include Flectorin®, Flectopar®, Flalgo®, and Weavor®. 
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 2.2 Product development rationale 
During the 1980s, IBSA together with the manufacturer Teikoku Seiyaku of Japan developed a 
medicated plaster containing as the active ingredient (NSAID) diclofenac epolamine (DHEP) 
1.293g/100g of paste spread on an unwoven cloth. This drug product meets the definition of 
‘medicated plaster’ in the European Pharmacopoeia40. The product is marketed as Flector® Tissugel 
1% in Europe and Flector® Patch 1.3% in the US. 
2.3 Choice of permeability enhancer 
Heparin is a naturally-occurring glycosaminoglycan found in the secretory granules of mast cells in 
different organs, particularly the lung, liver, heart and intestinal mucosa. The choice of strength for 
inclusion in the medicated plaster is within the range of existing marketed topical products and 
based on comparative permeability studies of medicated plaster formulations of diclofenac 
epolamine with or without heparin as excipient performed in vitro with a Franz cell diffusion system 
using different membranes (see Comparative in vivo drug release and permeation profiles section).  
The probable mechanism responsible for the permeability-enhancing properties of heparin 
has to be fully elucidated. As a polar, high molecular weight glycosaminoglycan, heparin is 
characterized by a high negative charge due to the presence of abundant sulfate and carboxylic 
groups in its structure. It is hypothesized that electrostatic repulsion forces between heparin and the 
less negatively charged, low molecular weight diclofenac epolamine might affect the diffusion flux of 
this molecule from the patch poultice through lipophilic membranes, with corresponding increased 
skin deposition and permeation. This behavior has been observed for other large highly-charged 
molecules, such as proteins, peptides, and oligonucleotides, where the charge may decrease, in vivo, 
the transepithelial electrical resistance and improve the permeation of the active ingredient41. 
However, to the best of our knowledge, these properties have not specifically been studied for 
heparin, and confirmation of the properties demonstrated in the DHEP Plus medicated plaster 
clinical development program for the role of heparin as a permeability enhancer await a suitably-
designed in vitro study.  
2.4 Development of the DHEP Plus medicated plaster 
Based on the rationale of providing improved clinical efficacy compared with the first generation 
marketed DHEP medicated plaster, a second-generation patch, DHEP Plus medicated plaster was 
developed, which is identical in composition to the first except for the addition of heparin as an 
excipient.  
2.5 Formulation of the drug product 
The medicated plaster is prepared by mixing the active ingredient with a viscous base of hydrophilic 
polymers (such as gelatin, carmellose sodium, sodium polyacrylate and povidone), sorbitol and 
water. The mixed base is spread on a backing cloth, the surface is covered with polypropylene plastic 
film (the “release liner”), and the molded cataplasm is cut to an appropriate size. Although the 
composition does not contain a true adhesive, the plaster is effectively adherent because of the 
presence of hydrophilic polymers and sorbitol, with the result that the plaster can be simply applied 
on the skin of the affected area. The medicated plaster contains abundant water, allowing the drug 
substance to be dissolved in an aqueous phase which helps to impart a cooling effect after 
application. The manufacturing and distribution of the poultice are performed in two steps following 
the manufacturing process. 
The formulation contains diclofenac epolamine as the active ingredient and a number of 
excipients with different roles, including viscosity enhancing agents, a chelating agent, humectants, 
pH buffers, preservatives (low levels of methyl- and propyl-paraben), coloring agents, fragrance and, 
finally but importantly, heparin as a permeability enhancing agent for the active ingredient, 
diclofenac epolamine. Of note, the formulation avoids the use of the solvent, dimethyl sulfoxide 
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 (DMSO), as a permeability enhancer, thus avoiding the garlic-like smell and potential toxic effects of 
DMSO. The medicated plaster consists of an unwoven cloth spread with a hydrophilic paste or 
hydrogel poultice which is protected by a plastic film (Figure 1).  
The DHEP Plus medicated plaster was developed to provide a convenient once-daily 
application, whereas other topical formulations of NSAIDs and heparinoids (e.g., ointments and gels) 
require frequent application and may adhere to clothing. In the form of a medicated plaster, the 
drug substance diclofenac epolamine has local analgesic and anti-inflammatory activity particularly 
suitable for the treatment of pain related to post-traumatic injuries of the musculoskeletal system 
while minimizing systemic exposure.  
2.6 Comparative in vivo drug release and permeation profiles 
Comparative in vitro dissolution testing of diclofenac epolamine performed according to European 
Pharmacopoeia protocol 2.9.4 (transdermal patches) during the development of the new 
formulation showed that both the DHEP Plus formulation and the reference marketed DHEP 
medicated plaster have the same dissolution profile. This indicates that the addition of heparin does 
not appear to induce any change in the physical or chemical characteristics of the plaster. The 
dissolution test profiles confirmed that more than 70% of diclofenac epolamine is released within 
180 minutes in both drug products.  
Comparison of the in vitro release and permeation of diclofenac epolamine from the 
reference marketed DHEP medicated plaster has been conducted with a Franz cell diffusion system 
using different membranes, and recently with the MatTek EpiDerm™ EPI-606-X System (standardized 
tridimensional skin surrogate models).  
The permeated diclofenac epolamine was analyzed using validated analytical methods. A 
plot of mean Franz cell permeation profiles of diclofenac epolamine from the reference marketed 
DHEP medicated plaster and the DHEP Plus medicated plaster is given in Figure 2. At 24 hours, mean 
permeated diclofenac epolamine was 122.69 µg/cm2 for the DHEP Plus medicated plaster, compared 
with 106.80 µg/cm2 for the reference marketed DHEP medicated plaster. Analysis of bioequivalence 
of the cumulative amounts of diclofenac epolamine permeated at any time performed on the log-
transformed data showed that the 90% confidence interval (CI) of the difference between the log-
transformed data of the two products was outside the range ± 0.2231 (i.e., 80%–125% of the log of 
the ratio between the data of two products) at every time point (Data not shown). Thus, the 
cumulative amounts of diclofenac epolamine permeated for the two products cannot be considered 
bioequivalent; the amount of diclofenac epolamine released from the DHEP Plus medicated plaster 
is greater than that from the marketed DHEP medicated plaster. 
Furthermore, permeation testing demonstrated that heparin is not released from the DHEP 
Plus medicated plaster; no heparin was detectable in the receiving chamber of the Franz Cell System 
used to evaluate permeation from the DHEP Plus medicated plaster under a range of test conditions. 
In conclusion, the increased permeability of diclofenac through the EpiDerm EPI-606-X 
membranes demonstrated that heparin, added in the plaster matrix, behaves as a permeability 
enhancer of the active ingredient. As the activated partial thromboplastin time (aPTT) was 
unchanged after DHEP Plus medicated plaster application42, confirming the absence of any heparin-
related anticoagulant activity, and residual heparin content in the plaster after 24 hours of 
cutaneous application in another study was not different from the initial content43, both findings 
support the conclusion that no heparin is released from the plaster. 
2.7 Clinical pharmacological objectives 
A series of studies were designed to assess specific clinical pharmacology and pharmacokinetic 
properties of the DHEP Plus medicated plaster (Table 1).  
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 2.8 Pharmacokinetic studies 
The pharmacokinetics of diclofenac epolamine when formulated as a medicated plaster with heparin 
as an excipient was investigated in three studies: Study CRO-PK-02-9242, CRO-PK-98-1344, and CRO-
PK-12-27243. 
2.81 Study CRO-PK-02-92 
Study CRO-PK-02-92 (Table 1) evaluated the percutaneous absorption of diclofenac epolamine and 
heparin after repeated cutaneous application in healthy volunteers42. Application of DHEP Plus 180 
mg medicated plaster twice daily for 6 consecutive days did not produce clinically relevant changes 
in activated partial thromboplastin time (aPTT) values from pre-dose values at any time point, 
demonstrating that heparin was not absorbed in systematically effective concentrations. Mean 
diclofenac plasma concentrations ranged between 1.44 and 2.36 ng/mL and were approximately 
500- to 1,000-times lower than the diclofenac Cmax achieved in plasma after oral administration of 
diclofenac sodium at the recommended therapeutic dose45. 
2.82 Study CRO-PK-98-13 
Study CRO-PK-98-13 (Table 1) was an open-label randomized, two-way crossover, multiple-dose 
study designed to assess the bioavailability of diclofenac by comparing the percutaneous absorption 
of diclofenac and heparin following application of DHEP Plus 180 mg medicated plaster and the 
reference marketed DHEP medicated plaster twice-daily (12-hour) for 7 days to the back of healthy 
volunteers at a single center44. 
Systemic exposure to diclofenac was low with both products, and there was no clinically-
significant increase in systemic exposure following application of the DHEP Plus medicated plaster 
compared with the reference DHEP medicated plaster (Table 2). Statistical comparison of the main 
pharmacokinetic parameters in the final phase showed very similar bioavailability for the Test and 
Reference plasters (Frel = 110.58 ± 46.71). Safety profiles for the two formulations were similarly 
satisfactory, with itching at the application site the only adverse event (AE) possibly related to the 
product. 
2.83 Study CRO-PK-12-272 
Study CRO-PK-12-272 (Table 1) was a two-part study that assessed the residual content of diclofenac 
epolamine and heparin in the DHEP Plus 180 mg medicated plaster after 24-hour application (Part I) 
and obtained data on the effects of three non-standard treatment conditions (moderate exercise, 
under occlusion and moderate heat exposure) on the percutaneous absorption of diclofenac 
following multiple applications of DHEP Plus 180 mg medicated plaster (Part II)43. There was no 
change in the residual content of heparin after 24 hours application (before 5,584.75 ± 356.35 – 
after 5,621.38 ± 363.46, Heparin (IU), mean ± standard deviation), demonstrating that heparin is not 
released from the patch and therefore available for percutaneous absorption. 
In Part II, mean diclofenac plasma concentrations measured before and after the last plaster 
application showed that, while both rate (maximum concentration; Cmax) and extent at steady state 
(AUCΤ) of diclofenac absorption for the three tested conditions were higher than for the standard 
(resting) condition, differences in time to maximum concentration (Tmax) values were not statistically 
significant (p = 0.2568). No treatment effect was observed (p = 0.0933). There was a sequence effect 
comprising a 10–20% increase in rate and extent of absorption for all three comparisons (p ≤ 
0.0471), which was considered unlikely to reflect a clinically-relevant increase in systematic exposure 
to diclofenac, which always remained >100 times lower than after a typical 50 mg oral dose of 
diclofenac. The combined usage of DHEP Plus 180 mg medicated plaster with occlusive or 
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 moderately heating wraps/bandages or the wearing of the plaster during moderate physical 
exercise, therefore, does not pose additional risks for patients. 
2.9 Pharmacodynamic study 
2.91 Affaitati, et al. 201546 
The primary aim of this study (Table 1) was to assess the effects of diclofenac epolamine on somatic 
pain sensitivity in 104 healthy asymptomatic subjects with a latent algogenic condition (hyperalgesia 
without spontaneous pain) of the deep tissues (subcutis and muscle) of the lower limbs after topical 
application of DHEP Plus 180 mg medicated plaster46. 
Both DHEP Plus 180 mg medicated plaster and DHEP medicated plaster increased the pain 
threshold to electrical stimulation compared with placebo, with a substantially greater increase with 
DHEP Plus 180 mg medicated plaster compared with the other groups over the treatment period 
both in the intention-to-treat (ITT) and per protocol (PP) population (Table 3). There was a 30% 
increase from baseline with the DHEP Plus medicated plaster, compared with 12% with the 
marketed DHEP medicated plaster. The results of the secondary variables (pain threshold to 
mechanical stimulation in muscle, and thickness of muscle at ultrasound examination) showed a 
trend similar to those obtained for electrical stimulation, even if they did not reach statistical 
significance due to the high variability observed (data not showed). 
The results indicate a higher efficacy of DHEP Plus 180 mg medicated plaster over the 
reference DHEP medicated plaster in increasing the pain threshold to electrical stimulation at the 
muscle level after daily application for 7 consecutive days, suggesting that the addition of heparin to 
diclofenac in a patch formulation could be useful to treat pain conditions even in the absence of 
objective signs of injury, edema or hematoma. 
2.10 Pharmacology conclusions 
The pharmacokinetic and pharmacodynamic data are collectively consistent with the concept that 
the presence in the formulation of a small amount of heparin enhances the clinical activity of DHEP 
Plus 180 mg medicated plaster compared with the reference DHEP medicated plaster46. However, 
since heparin is entrapped in the plaster poultice, as shown by the lack of heparin release in the in ex 
vivo permeation studies and of any modification in heparin content in plasters after 24 hours of in 
vivo application (Study CRO-PK-12-272)43, the enhanced activity is not due to a direct effect of 
heparin on local pain and inflammation, but instead to the enhanced release of diclofenac from the 
poultice, resulting in greater local bioavailability of the active drug47. 
The extent of this increase is insufficient to alter the systemic exposure of patients to 
diclofenac following DHEP Plus 180 mg medicated plaster when compared with DHEP medicated 
plaster (Study CRO-PK-02-92 and Study CRO-PK-98-13)42,44. Consequently, the decision to include 
heparin in the formulation as an excipient in the product development of the DHEP Plus 180 mg 
medicated plaster, with the unique role of enhancer of diclofenac, can be considered consistent with 
the evidence from the above studies. The probable mechanism through which heparin enhances the 
effects of topical diclofenac has been hypothesized to be that, since heparin is a large (≈10,000 
Daltons), highly electronegative, presumably immobile molecule uniformly distributed throughout 
the adhesive/sticky plaster matrix, it may act by increasing the diffusibility of the much smaller, 
negatively-charged active ingredient via repulsive forces.  
3. Clinical efficacy studies  
Three pivotal studies48-50 have investigated the efficacy of the DHEP Plus 180 mg medicated plaster 
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 in humans. Two of these studies were conducted with the objective of showing the superiority of 
DHEP Plus over the reference DHEP mg medicated plaster in reducing pain on movement at Day 3 
compared with baseline (primary efficacy objective)48,49, while the third also assessed pain on active 
mobilization as a secondary endpoint, to confirm the superiority of DHEP Plus 180 mg medicated 
plaster over placebo50. A summary of the characteristics and design of the pivotal clinical trials is 
presented in Table 4. 
The efficacy and safety assessments used in these studies were standard, widely used and 
recognized as reliable, accurate, relevant to both the tested treatments and the medical condition, 
and able to discriminate between effective and ineffective products. Sample sizes were calculated to 
demonstrate appropriate differences between groups, based on results from previously conducted 
trials of the reference DHEP mg medicated plaster with very similar study designs. It should be 
emphasized that, although designed to use similar outcome measures, there was inevitably some 
heterogeneity in patient populations and dose regimens in these studies, and it is not intended that 
direct comparisons of efficacy be made between studies. 
Pain on movement as a primary efficacy criterion was based on clinical relevance in relation 
to the population/conditions under investigation (ankle sprain, muscle contusion), and analyzed 
using the 0–100 mm Visual Analog Scale [VAS]), the latter a validated, reproducible, commonly used 
index of pain. In addition, the use of pain on movement as a primary criterion for the evaluation of 
drug activity is recommended by current regulatory and scientific guidelines (European Medicines 
Agency [EMEA] documents CPMP/EWP/784/97 Rev. 1, 23 July 1998, and CPMP/EWP/612/00, 21 
November 2002). 
A further non pivotal study investigated the time to complete hematoma dissolution and 
pain parameters in patients with mild-to-moderate muscle contusions and strains (Table 4)51. 
Overall, the phase III studies, which enrolled patients suffering from minor post-traumatic 
injuries, consistently found that DHEP Plus 180 mg medicated plaster was significantly more 
effective in reducing pain than the DHEP medicated plaster or vehicle (placebo plaster) (Table 5)48-51. 
Both active formulations were also significantly more effective than placebo. In DHEP medicated 
plaster recipients across all the randomized-controlled trials, the mean number of applied patches 
per patient was 10.0 ± 3.3, treatment compliance issues were noted in only 2.3% of patients, and 
there were no cases of incorrect plaster application recorded. 
Overall, analysis of the analgesic effects of DHEP Plus 180 mg medicated plaster (VAS score 
reductions in pain on movement) in the pivotal studies suggests comparable to superior efficacy to 
other topical NSAIDs based on results of double-blind, randomized, placebo-controlled clinical trials 
published in the medical literature (Figure 3), although definitive conclusions cannot be made in the 
absence of specific inter-drug comparisons.  
Results reported in the three pivotal studies for DHEP Plus 180 mg medicated plaster show a 
VAS reduction ranging from 9.4 to 14.7 mm on a 0–100 mm scale, compared with placebo patients 
after 7 days of treatment, which can be regarded as an acceptable therapeutic outcome within the 
topical NSAID class. Furthermore, the mean reduction of VAS ranging between 4.9 and 7.1 mm 
achieved with DHEP Plus 180 mg medicated plaster compared with the DHEP medicated plaster in 
the same studies is at least comparable, and in some cases higher, than those obtained with other 
NSAIDs when compared with placebo. 
3.1 Costantino et al. 2011  
The primary aim of this study48 (Table 4) was to compare the efficacy of DHEP Plus 180 mg 
medicated plaster with the reference marketed DHEP medicated plaster in the treatment of acute, 
mild-to-moderate ankle sprain involving the external lateral ligaments.  
DHEP Plus 180 mg medicated plaster was significantly more effective than DHEP medicated 
plaster in the relief of ‘pain on movement’ after 3 days of treatment (Table 5), as well as over the 
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 entire 7-day treatment period. Both DHEP Plus 180 mg medicated plaster and DHEP medicated 
plaster were significantly more effective than placebo (Table 5).  
DHEP Plus 180 mg medicated plaster and the marketed DHEP medicated plaster produced a 
significantly greater relief in terms of ‘spontaneous pain at rest’ and of ‘pain while leaning on the 
injured limb only’, as compared with placebo. In addition, patients treated with DHEP Plus 180 mg 
medicated plaster consumed fewer tablets of rescue medication (paracetamol) than did patients 
treated with DHEP and placebo. 
Overall, the Investigator’s and patient’s opinion on efficacy favored DHEP Plus 180 mg 
medicated plaster as compared with DHEP and placebo. 
3.2 Hoffmann et al. 2012 
The objective of this study49 (Table 4) was to investigate if the DHEP Plus 180 mg medicated plaster 
was significantly more effective than the reference DHEP medicated plaster for pain reduction in 
patients with mild-to-moderate contusions with the presence of hematoma. Other objectives 
included pain on movement assessed daily throughout the 2-week treatment period, the presence 
of a superficial hematoma and time needed to reach a complete hematoma disappearance, and 
local and general safety.  
DHEP Plus medicated plaster was significantly more effective at reducing pain on Day 3 in 
the primary analysis (Table 5). Pain on movement (VAS), as assessed by patients, improved faster in 
the DHEP Plus 180 mg medicated plaster group, compared with DHEP medicated plaster and placebo 
plaster (Figure 4). Overall statistical efficacy analyses confirmed the superiority of DHEP Plus 180 mg 
medicated plaster over the other two groups; it can be concluded that DHEP Plus 180 mg medicated 
plaster is significantly more effective than DHEP medicated plaster in relieving pain from recent 
mild-to-moderate muscle contusions when applied daily for as long as 14 days. Both DHEP Plus 180 
mg medicated plaster and DHEP medicated plaster were proven to be significantly more effective 
than a placebo plaster, while showing a comparably favorable, placebo-like local and general safety 
profile. 
3.3 Coudreuse and De Valthaire 2010  
The following study50 (Table 4) compared the efficacy and tolerability of DHEP Plus 180 mg 
medicated plaster with placebo for the treatment of painful minor lateral ankle sprain with 
perimalleolar edema.  
Patients treated with DHEP Plus 180 mg medicated plaster experienced a nearly significantly 
greater reduction of edema within the first 3 days (p = 0.06) ) compared with placebo, reaching 
significance after seven days of treatment (p = 0.003. ANOVA analysis for the evolution of the 
perimalleolar edema over the entire 7-days period showed a significantly superior treatment effect 
for the DHEP Plus 180 mg medicated plaster group (p = 0.01). 
The DHEP Plus 180 mg medicated plaster also reduced spontaneous pain significantly more 
effectively than placebo (Table 5) at all post-treatment evaluation time points (data not shown) 
except at 2 and 5 hours, despite higher pain at inclusion (p = 0.01) in patients in the active plaster 
group. At the end of treatment period, global judgment of treatment efficacy by physicians was in 
favor of DHEP Plus 180 mg medicated plaster compared with placebo (p < 0.05); the effectiveness of 
treatment was judged to be good-to-excellent in 85% of DHEP Plus 180 mg medicated plaster- and in 
70% of placebo-treated patients. 
The results confirmed that once-daily application (for 24 hours) of DHEP Plus 180 mg 
medicated plaster in double-blind conditions was superior to placebo (vehicle) in controlling and 
reducing pain and counteracting joint swelling in patients suffering from a mild-to-moderate sprain 
of the external lateral ligament of the ankle. 
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 3.4 Klainguti et al. 2010  
The primary aim of the non-pivotal study51 (Table 4) was to assess the time to complete hematoma 
resolution in patients with mild-to-moderate muscle contusions and strains accompanied by 
superficial hematoma and spontaneous pain. Pain on movement and pain at rest were also assessed.  
Starting from Day 4 of treatment and throughout the entire treatment period, patients 
treated with DHEP Plus 180 mg medicated plaster had a cumulative rate of hematoma resolution 
significantly higher than those receiving either DHEP medicated plaster or placebo (between-group 
difference p < 0.05, for both comparisons). Cox’s proportional hazards regression analysis showed 
that there was a significantly higher likelihood of successful hematoma dissolution with DHEP Plus 
180 mg medicated plaster than DHEP medicated plaster (p = 0.03) and placebo (p = 0.02), 
representing a 62% greater chance of achieving complete hematoma dissolution within 10 
treatment days with DHEP Plus 180 mg medicated plaster. 
According to patient self-ratings, significantly greater reductions in pain on movement were 
reported in the DHEP Plus 180 mg medicated plaster and in the DHEP group (data not shown) 
compared with the placebo group after 2 and 3 days of treatment (Table 5).  
The total amount of rescue medication consumed by patients in the placebo group during 
the first three treatment days was higher than in patients treated with DHEP Plus 180 mg medicated 
plaster or DHEP medicated plaster. 
The results demonstrate that the DHEP Plus 180 mg medicated plaster is more effective than 
the reference marketed DHEP medicated plaster in fostering hematoma resolution frequently 
associated with mild-to-moderate sports-related injuries, but not with regard to pain management if 
treatment is limited to 12 hours per day. 
3.5 Comparative outcomes (number needed to treat) 
In the clinical efficacy studies that assessed analgesic effects in terms of reduction of pain on 
movement48-50, a higher proportion of patients treated with the DHEP Plus medicated plaster 
compared with placebo achieved success (defined as ≥50% reduction of pain on movement as 
assessed by the patient on a VAS of 0-100 mm) after 3 or 7 days of once-daily plaster application 
(Table 6). For the DHEP Plus medicated plaster, the NNT for one patient to achieve clinical success 
was 4.00 after 7 days of treatment (95% CI 3.04–5.83) (Table 6).   
4. Safety 
The DHEP Plus 180 mg medicated plaster was developed as a formulation identical to that of the 
reference marketed DHEP medicated plaster, except for the presence of a small amount of 
unfractionated heparin sodium per medicated plaster. As in vitro permeation studies47, and in vivo 
pharmacodynamic43 and pharmacokinetic studies42,44 have demonstrated that heparin is not 
released from the plaster, and very low amounts of diclofenac are systemically distributed after 
topical application of the DHEP Plus medicated plaster, the safety of the DHEP Plus 180 mg 
medicated plaster was expected to be similar to that of the marketed DHEP medicated plaster; i.e. 
any tolerability issues were expected to be local skin reactions at the application site.  
Safety and tolerability data collected in Studies CRO-PK-02-92, EU01.2002 and 13FCDN-
FHp0342,52,53 also demonstrated excellent local tolerability of the DHEP Plus medicated plaster, with 
very low irritation scores that were superimposable with those of the marketed DHEP medicated 
plaster or placebo and with no apparent hypersensitization reactions.  
4.1 Adverse events in the clinical trials 
In the phase III clinical trials (Table 4), all AEs that occurred during the study period (from enrollment 
and throughout the whole treatment period) of the phase III placebo- and/or active-controlled 
clinical trials, irrespective of their relation to treatment were to be reported by the Investigator in 
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 the patient’s case report form, and were to be followed up if necessary until resolution or up to 4 
weeks after the end of the treatment period. The nature, seriousness, and intensity of the AE, as 
well as and their correlation with the treatment received, were recorded. Additionally, patients were 
instructed to record any untoward effects suffered over the course of the study in their diaries, 
irrespective of their perceived relationship to treatment. At each control visit, the investigator 
monitored AEs and patient diaries were reviewed by the doctor during clinic visits.  
The most frequently observed AEs following treatment with DHEP Plus 180 mg medicated 
plaster were cutaneous AEs at the plaster application site, including pruritis, irritation, rash, edema 
and warmth. These reactions occurred at similar rates among all treatment groups (Table 7), and of 
the few systemic AEs reported in the trials, none were considered to be related to treatment. 
No new safety concerns related to the DHEP Plus medicated plaster were identified. 
4.2 Drug interactions and special considerations 
Due to the very low levels of systemic absorption of diclofenac from the DHEP Plus 180 mg 
medicated plaster and following the experience with the marketed DHEP medicated plaster, no 
interaction with other concomitant drugs has been observed or is expected to be observed in post-
marketing use. Data to support the use of DHEP Plus 180 mg medicated plaster in pregnancy or 
lactation are lacking. Consequently, as a precaution, DHEP Plus 180 mg medicated plaster must not 
be used during the first and second trimester of pregnancy and it is contraindicated starting from the 
sixth month of pregnancy, and the medicated plaster should only be used during lactation under 
advice from a healthcare professional.  
Following the recommendations released for the use of systemic and topical formulations of 
diclofenac in pediatric populations contained in the Public Paediatric Assessment Report 
(DE/W/001/pdWS/001), it is intended that the use of DHEP Plus 180 mg medicated plaster should be 
limited to patients 16 years of age or older. 
 
5. Benefit / risk overview and conclusions  
DHEP Plus 180 mg medicated plaster was found to be significantly more effective in reducing pain 
than the reference marketed DHEP medicated plaster in the two pivotal phase III studies enrolling 
patients suffering from minor post-traumatic injuries, with both active formulations also being 
significantly more effective than placebo48,49. Therefore, a claim for the new formulation to be used 
for the treatment of localized pain and inflammation of muscle-skeletal structures, associated with 
post-traumatic and/or rheumatic conditions, seems to be adequate and justified. 
The DHEP Plus 180 mg medicated plaster is applied as a once-daily dose regimen, which is 
very convenient for the patient, with a recommended maximum 14-day treatment duration. The 
clinical trial program showed that compliance with the DHEP Plus medicated plaster is excellent, and 
an absence of incorrect application of the plasters supports the convenience and ease of use of the 
product. However, as with all active pharmaceutical products, DHEP Plus medicated plasters should 
be used with appropriate regard to the indication, with dosage and application instructions 
consistent with individual patient treatment goals. 
The data generated during the clinical development program are collectively consistent with 
the concept that the role of heparin in the increased clinical activity of DHEP Plus 180 mg medicated 
plaster in comparison to the reference DHEP medicated plaster is not due to a direct effect of this 
highly sulfated glycosaminoglycan on local pain and inflammation, but to the enhanced movement 
of the diclofenac from the poultice, improving local tissue bioavailability of the active ingredient. 
Therefore, the decision to include heparin in the formulation would seem to be adequately justified. 
Moreover, the new DHEP Plus medicated plaster appears to be characterized by a placebo-
like safety profile, with minor local skin reactions at the site of application being the only medically 
relevant events.  
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 DHEP Plus medicated plaster with the presence of heparin as permeability enhancer, on the 
basis of all the available scientific evidence, thus represents a new and effective therapeutic option 
for the local symptomatic treatment of acute minor painful musculoskeletal conditions (i.e. affecting 
joints, muscle, tendon and ligaments), with a positive benefit/risk profile.  
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 Tables 
Table 1 Clinical pharmacology, pharmacokinetic and pharmacodynamic studies. 
Study ID Study design and 
assessments 
Objective Test products; dose 
regimen;  
route of 
administration 
Subjects, N 
Study CRO-
PK02-9242 
Open-label, single 
center study. 
aPTT measured pre-
dose and 6 hours 
post-dose during 
daily application and 
at specified intervals 
on the last 
application day. 
Diclofenac plasma 
concentrations 
measured at 
specified intervals on 
days 1, 5, and 6. 
To evaluate the risk 
of epicutaneous 
absorption of heparin 
sodium after 
repeated application 
of the new 
medicated plaster 
using aPTT values (a 
marker for the 
systemic absorption 
of heparin) and 
plasma 
concentrations of 
diclofenac. 
DHEP Plus 180 mg 
medicated plaster 
bid on the back for 6 
consecutive days. 
Healthy male & 
female volunteers 
(n = 12) 
Study CRO-
PK-98-1344  
Open-label, 
randomized, two-way 
crossover, multiple 
dose study. 
Blood samples were 
obtained on Day 8 
(Period 1) and Day 22 
(Period 2) pre-dose 
and at 12 pre-
specified times until 
24 hours post-dose. 
To assess the 
systemic 
bioavailability and 
bioequivalence of 
DHEP Plus 180 mg 
medicated plaster 
and DHEP medicated 
plaster after 
repeated 
epicutaneous 
administration.  
a) DHEP Plus 180 mg 
medicated plaster, 
b) DHEP medicated 
plaster bid to the 
right lumbar region 
for 7 consecutive 
days plus once on 
Day 8 with a 7-day 
washout period 
between each study 
period. 
Healthy male & 
female volunteers  
Phase 1 
(preliminary) 
(n = 4) 
Phase 2 (final) 
(n = 18, 16 
analysed) 
Study CRO-
PK-12-27243 
Open-label, single 
center, four-way 
crossover, controlled 
study. 
Diclofenac plasma 
pharmacokinetic 
parameters were 
measured according 
to validated 
analytical methods. 
1) To assess the 
residual content of 
diclofenac epolamine 
and heparin in DHEP 
Plus medicated 
plaster after 24 hours 
of application. 
2) To assess the 
impact of exercise, 
occlusion and heat 
on diclofenac 
absorption and 
systemic 
bioavailability 
following repeated 
plaster application.  
1) Cutaneous 
application of one 
DHEP Plus 
medicated plaster 
for 24 hours to the 
inner upper part of 
each arm. 
2) Single cutaneous 
application of DHEP 
Plus 180 mg 
medicated plaster 
od to the front thigh 
for 4 consecutive 
days in each of the 4 
conditions (resting; 
moderate exercise; 
application under an 
occlusive bandage; 
1) Healthy 
volunteers (n = 
24) 
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 exposure to 
moderate heat) with 
a ≥5-day washout 
period between 
each study period. 
Study 
07I/FHp0446 
Prospective, single 
center, double-blind, 
randomized, 4-arm 
parallel group, 
controlled study. 
Pain thresholds to 
pressure and 
electrical 
standardized 
stimulation were 
measured at the level 
of the vastus lateralis 
muscle and overlying 
area using a Fischer’s 
algometer (pressure 
pain threshold) and a 
computerized, 
constant-current, 
electrical stimulator. 
Primary: to assess the 
effects of diclofenac 
on pain thresholds to 
electrical stimulation 
of the cutis, subcutis, 
and muscle when 
topically applied as 
DHEP Plus 180 mg 
medicated plaster in 
asymptomatic 
subjects with a latent 
algogenic condition 
(e.g., from previous 
knee micro-traumatic 
events or latent 
myofascial trigger 
points). 
a) DHEP Plus 180 mg 
medicated plaster 
b) DHEP medicated 
plaster 
c) Heparin plaster 
(i.e., the vehicle of 
DHEP Plus 180 mg 
medicated plaster) 
d) Placebo plaster, 
od to the cutaneous 
area overlying the 
vastus lateralis 
muscle for 7 
consecutive days. 
104 (4 groups of 
26) subjects (84 
women, 20 men, 
mean age 42.2 ± 
13.3 years), with 
deep somatic 
hyperalgesia in 
one thigh based 
on standardized 
electrical 
stimulation 
measurements. 
Abbreviations: aPTT, activated partial thromboplastin time; bid, twice-daily; od, once-daily. 
 
 
 
Table 2 Pharmacokinetic parameters of diclofenac epolamine in healthy volunteers (n = 16). 
 DHEP Plus 180 mg medicated plaster DHEP medicated plaster 
Cssmax, ng/mL 3.51 ± 2.04 3.59 ± 2.09 
Cssmin, ng/mL 1.20 ± 0.57 1.23 ± 0.56 
Tssmax, hours 3.66 ± 3.88 2.16 ± 1.85 
AUCss, mg/mL•h 23.42 ± 11.93 22.48 ± 10.44 
Values are mean ± standard deviation. 
Abbreviations: AUCss, area under the concentration/time curve at steady state; Cssmax/Cssmin 
maximum/minimum plasma concentration at steady state; Tssmax, time to reach maximum plasma 
value. 
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 Table 3 Adjusted mean values for change from baseline of pain threshold to electrical muscle 
stimulation (mA) of muscle as compared to the mean values without adjustment for the covariates46. 
Plaster DHEP Plus DHEP Heparin Placebo 
Day 4 (Mean ± SD)  0.29 ± 0.38 0.15 ± 0.27 0.06 ± 0.33 -0.09 ± 0.43 
Day 4 (Adjusted mean for gender)  0.27 0.13 0.03 -0.12 
Day 4 (Adjusted mean for subcutis 
thickness)  
0.28 0.15 0.06 -0.09 
Day 8 (Mean ± SD)  0.40 ± 0.46*† 0.16 ± 0.38‡ 0.06 ± 0.38 -0.02 ± 0.28 
Day 8 (Adjusted mean for gender)  0.38 0.14 0.03 -0.04 
Day 8 (Adjusted mean for subcutis 
thickness)  
0.40 0.17 0.06 0.00 
*p = 0.0307 vs. the reference DHEP medicated plaster. †p = 0.002 and p < 0.0001, respectively, vs. 
Heparin plaster and placebo plaster. ‡p = 0.0299 vs Placebo  
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Table 4 Characteristics and design of the clinical trials program in the development of the DHEP Plus 
180 mg medicated plaster. 
Study ID Study design / 
type of 
control 
Objectives Test products; 
dose regimen; 
route of 
administration 
Subjects, 
N 
Patient 
diagnoses 
Pivotal studies 
Study 06EU-
FHp0348  
Multicenter 
(13 sites), 
multinational 
(Italy, Poland, 
Ukraine), 
prospective, 
double-blind, 
vs. active and 
placebo-
controlled, 3-
arm parallel 
group 
randomized 
clinical study. 
Assessments 
at clinic 
scheduled at 
inclusion (Day 
1), and after 
3, and 7 days, 
plus daily 
patient 
evaluations at 
home (diary), 
and follow-up 
(phone) 
contact on 
day 14. 
Primary: to 
demonstrate that 
DHEP Plus 180 mg > 
DHEP medicated 
plaster in terms of 
reduction of pain 
on movement. 
Secondary: to 
demonstrate that 
DHEP Plus 180 mg 
and DHEP 
medicated plaster > 
Placebo, in pain 
reduction, rescue 
medication 
consumption, 
edema extension, 
pain at rest, pain 
while leaning on 
the injured limb, 
overall treatment 
efficacy.  
Safety: local 
(cutaneous) 
tolerability, local 
and systemic safety 
(AEs). 
a) DHEP Plus 
medicated 
plaster, 1 
plaster/day 
b) DHEP 
medicated 
plaster, 1 
plaster/day 
c) Placebo, 1 
plaster/day 
topically 
applied on the 
most painful 
area during 7 
days 
a) 142 / 
142 
b) 146 / 
142 
c) 142 / 
140 
Outpatients 
with acute ankle 
sprain, involving 
the external 
lateral ligament, 
occurred <48 
hours before 
inclusion; sprain 
severity grade I 
or II; untreated; 
pain on 
movement ≥ 50 
mm (VAS); 
presence of 
peri-malleolar 
edema. 
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 Study 05DCZ-
FHp1149 
Multicenter 
(20 sites), 
multinational 
(Germany, 
Czech 
Republic), 
prospective, 
double-blind, 
vs. active and 
placebo-
controlled, 3-
arm parallel 
group 
randomized 
clinical study. 
Assessments 
at clinic 
scheduled at 
inclusion (Day 
1), and after 7 
and 14 days, 
plus daily 
patient 
evaluations at 
home (diary). 
Primary: to 
demonstrate that 
DHEP Plus 180 mg > 
DHEP medicated 
plaster in terms of 
reduction of pain 
on movement.  
Secondary: to 
demonstrate that 
DHEP Plus 180 mg 
and DHEP 
medicated plaster > 
placebo in pain 
reduction, rescue 
medication 
consumption, 
bruising extension, 
pain at rest, overall 
treatment efficacy.  
Safety: local 
(cutaneous) 
tolerability, local 
and systemic safety 
(AEs). 
a) DHEP Plus 
medicated 
plaster, 1 
plaster/day 
b) DHEP 
medicated 
plaster, 1 
plaster/day 
c) Placebo, 1 
plaster/day 
topically 
applied on the 
most painful 
area during 14 
days 
a) 121 / 
121 
b) 115 / 
115 
c) 119 / 
118 
Outpatients 
with unilateral 
mild-to-
moderate 
muscle 
contusion of 
upper or lower 
limbs, occurred 
<72 hours from 
inclusion, pain 
on movement 
≥50 mm (VAS), 
presence of 
superficial 
hematoma 
(bruising). 
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 Study 18-12-
9850 
Multicenter 
(18 French 
sites), 
prospective, 
double-blind, 
vs. placebo-
controlled, 2-
arm parallel 
group 
randomized 
clinical study. 
Assessments 
at clinic 
scheduled at 
inclusion (Day 
1), and after 
3, and 7 days, 
plus daily 
patient 
evaluations at 
home (diary): 
every hour 
during the 6 
hours 
following the 
1st plaster 
application, 
morning, 
noon and 
evening the 
2nd and 3rd 
day. 
Primary: to 
demonstrate the 
efficacy and the 
safety of DHEP Plus 
180 mg vs. Placebo 
in terms of 
perimalleolar 
edema reduction. 
Secondary: to 
demonstrate the 
efficacy and the 
safety of DHEP Plus 
180 mg vs. Placebo 
in terms of pain on 
movement (VAS), 
at rest, on pressure 
reduction, rescue 
medication 
consumption, 
overall treatment 
efficacy.  
Safety: local 
(cutaneous) 
tolerability, local 
and systemic safety 
(AEs). 
a) DHEP Plus 
medicated 
plaster, 1 
plaster/day 
b) Placebo, 1 
plaster/day 
topically 
applied on the 
most painful 
area during 7 
days 
a) 120 / 
117 
b) 120 / 
117 
Outpatients 
with painful, 
minor ankle 
sprain involving 
the external 
lateral ligament, 
occurred <48 
hours before 
inclusion; 
untreated; pain 
on movement ≥ 
50 mm (VAS); 
presence of 
peri-malleolar 
edema 
(difference of  
20 mm in 
submalleolar 
perimeter vs. 
the healthy 
ankle. 
Non-pivotal study 
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99CH/FHp0251 
Multicenter 
(18 sites in 
Switzerland, 
Hungary and 
Italy), 
prospective, 
double-blind, 
vs. placebo-
controlled, 3-
arm parallel 
group 
randomized 
clinical study. 
Swelling 
assessed at 
clinic at 
inclusion (Day 
1) and 
evaluated by 
the patients 
every evening 
and the 
investigator 
at follow-up 
visits after 3 
and 10 days 
using a 4-
point severity 
scale. 
Primary: time to 
complete 
hematoma 
dissolution. 
Secondary: Pain on 
movement (VAS) 
and pain at rest 
(VAS) for DHEP Plus 
180 mg vs. DHEP 
medicated plaster 
vs. Placebo. 
Safety: local 
(cutaneous) 
tolerability, local 
and systemic safety 
(AEs). 
a) DHEP Plus 
medicated 
plaster, 1 
plaster /day 
b) Placebo, 1 
plaster /day 
c) DHEP 
medicated 
plaster, 1 
plaster /day 
topically 
applied at the 
injured site 
and left in 
place for 12 
consecutive 
hours a day 
for 10 days. 
a) 65 
b) 62 
c) 60 
Outpatients 
with mild-to-
moderate 
muscle 
contusions and 
sprains of upper 
or lower limb 
with a 
superficial 
hematoma ≤ 
140 cm2 and 
spontaneous 
pain ≥ 40 mm 
(VAS), occurred 
<72 hours 
before 
inclusion. 
Abbreviations: AE, adverse event; VAS, visual analogue scale. 
 
 
 
Table 5 Summary of efficacy evaluations of DHEP Plus 180 mg medicated plaster versus Controls. 
Results are described as incremental effects in terms of pain reduction compared to a placebo 
plaster or DHEP medicated plaster. Clinical Overview Summary of the clinical development program 
of the DHEP Plus 180 mg Medicated Plaster, IBSA Farmaceutici Italia Srl, Italy internal data. 
 
Study ID Reference 
control 
Therapeutic 
indication 
VAS Δ at ‘pain on movement’ from 
baseline 
(DHEP Plus 180 mg medicated plaster vs. 
Control) 
Costantino 201148 Placebo plaster Acute ankle sprain  Day 3: -10.05 mm (p < 0.001) 
Coudreuse 201050 Day 0/6h: -7.00 mm (p < 0.001) 
Hoffmann 201249 Muscle contusion 
of upper or lower 
Day 3: -13.9 mm (p < 0.001) 
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Klainguti 2010a51 Muscle contusion 
or muscle strain 
with a superficial 
hematoma  
Day 2: -4.5 mm (p <0.05) 
Costantino 201148 DHEP 
medicated 
plaster 
Acute ankle sprain  Day 3: -5.43 mm (p = 0.004) 
Hoffmann 201249 Muscle contusion 
of upper or lower 
limbs  
Day 3: -7.6 mm (p < 0.001) 
aIn this study, DHEP Plus was applied daily for a 12-hour period, while in the other studies DHEP Plus 
was applied for 24 hours/day; the difference in the application duration likely explains the lower 
analgesic effects observed in this study as compared to the other studies. 
Abbreviation: VAS, visual analogue scale. 
 
 
 
Table 6 Proportion [n / N (%)] of subjects achieving success, defined as ≥50% reduction of pain on 
movement as assessed by the patient on a visual analogue scale (0-100mm) compared with baseline, 
after 3 to 7 days of once-daily plaster application, by study and by treatment group, with relevant 
number needed to treat (NNT). 
 
Study no. / ID Assessment 
time point 
DHEP Plus 180 
mg medicated 
plaster 
Placebo plaster NNT (95% CI) NNT (95% CI)  
at Day 7 
(Studies 1 & 2 
pooled) 
1 / 06EU-
FHP0348 
Day 7 131/142 (92) 106/140 (76) 6.05 (4.02 – 
12.21) 
4.00 (3.04 – 
5.83) 
2 / 05DCz-
FHp1149 
Day 7 75/119 (63) 32/116 (28) 2.82 (2.11 – 
4.25) 
3 / 18-12-9850 Day 3 51/117 (44) 37/116 (32) 8.55 (4.16 – 
n.c.) 
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Table 7 Adverse events in phase III placebo- or active-controlled studies in the DHEP Plus medicated 
plaster clinical development program. 
 DHEP Plus 180 mg 
medicated plaster  
(n = 445) 
DHEP medicated plaster  
(n = 319) 
Placebo 
(n = 436) 
Total AEs, n (%) 24 (5.39) 26 (8.15) 36 (8.25) 
Patients with AEs, n (%) 17 (3.82) 14 (4.38) 26 (5.96) 
Application site AEs, n 
(%) 
11 (2.47) 14 (4.38) 24 (5.50) 
Patients with 
application site AEs, n 
(%) 
8 (1.79) 8 (2.50) 18 (4.12) 
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Figure legends 
Figure 1 Schematic representation of the medicated plaster, consisting of a polypropylene film 
release liner which adheres to a hydrophilic paste applied to an unwoven polyester felt backing 
cloth. Each plaster consists of 14 g of paste that contains 180 mg of diclofenac epolamine and 5,600 
IU (approximately 28 mg) of heparin sodium in a 10 cm x 14 cm plaster. The quantity of paste spread 
on a plaster, 1000 mg/m2, was designed to prevent a decrease in adhesive strength of the plaster 
resulting from evaporation of water during the application. The plasters are packed in a composite 
material envelope; in use, the patient removes the release liner and applies the self-adhesive plaster 
to the area being treated. Image courtesy of IBSA Institut Biochimique S.A.  
Figure 2 Comparative cumulative amount of diclofenac epolamine permeation over time for the 
reference marketed DHEP medicated plaster and the DHEP Plus medicated plaster measured 
through the MatTek EpiDerm™ EPI-606-X membrane. Study DRT-18.125.275b47. 
Figure 3 Reported visual analog scale (VAS) pain reductions compared with placebo for DHEP Plus 
180 mg medicated plaster and other topical nonsteroidal anti-inflammatory drugs (NSAIDs). Unless 
otherwise stated, data (difference vs. placebo in average score on a 100-mm VAS) are after 7 days of 
treatment49,54-58.  
Figure 4 Effects of pain on movement during the two-week study period in patients with mild-to-
moderate contusions in the presence of hematoma and treatment with standard DHEP medicated 
plaster versus DHEP Plus medicated plaster versus placebo. Reproduced with permission49. 
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